Business Context and Reporting Period
This Form 8-K Current Report was filed by Ventrus Biosciences, Inc. (noted as Assembly Biosciences in metadata) on September 13, 2013. The report details the entry into a material definitive agreement regarding the company's equity financing capabilities.
Key Financial Metrics and Agreements
The filing does not report standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it discloses specific terms of an amended sales agreement:
- Agreement Type: Amendment to a Controlled Equity Offering SM sales agreement with Cantor Fitzgerald & Co.
- Additional Offering Capacity: Up to $20,521,567 in common stock shares may be issued and sold.
- Previous Sales: $4,417,483 of shares were previously sold under the original agreement.
- Commission Rate: 3.0% of the gross sales price per share.
- Market: Sales will occur on the NASDAQ Capital Market.
Material Changes
The primary material change is the expansion of the company's ability to raise capital through an "at-the-market" offering. The amendment increases the total potential value of shares available for sale under the agreement by adding the new $20.5 million capacity to the existing framework.
Outlook, Risks, and Management Commentary
Management commentary is limited to the mechanics of the agreement. The company retains the right to instruct Cantor regarding price, time, or size limits. The filing notes that the description of the amendment is qualified by the full text of the agreement filed as Exhibit 1.7. No specific forward-looking guidance on revenue or product development is provided in this document.
Key Facts for Investor Verification
- Verify the total remaining capacity under the amended sales agreement ($20.5 million).
- Confirm the 3.0% commission structure and its impact on net proceeds from future sales.
- Review the full text of Amendment No. 1 (Exhibit 1.7) for specific conditions or termination rights not detailed in the summary.
- Note that this filing does not contain updated financial statements or operational results.